Beacon Equity picked to provide an investment report featuring Cord Blood America Inc.
In the report, the analyst notes:
"For the three months ended September 30, 2009, total revenue decreased approximately $90,000, or 9.6% to approximately $0.8 million. . CBAI's revenues remained approximately the same in the comparative periods at $0.8 million. CBAI remains focused on strategic organic growth and accretive acquisition strategies, which management hopes will reduce or eliminate continuing losses and negative cash flow.
"CBAI recently announced that it has signed a Letter of Intent to process and store cord blood specimens for BioCells Inc.... BioCells is already the second largest stem-cell storage company in Argentina with annual revenues of 1.5M (USD)... The deal between CBAI and BioCells is pending due diligence, and if it is completed successfully, anticipates the contract closing in the first quarter of 2010."
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Cord Blood America Inc. (CBAI) is engaged in the business of collecting, testing, processing and preserving umbilical cord blood. The Company is primarily a holding company whose subsidiaries include Cord Partners Inc., CorCell Co. Inc., CorCell Ltd., CBA Professional Services Inc. D/B/A BodyCells Inc., CBA Properties Inc., Career Channel Inc., D/B/A Rainmakers International, and Family Marketing Inc. In addition, the Company provides private cord blood stem cell preservation services to families in the United States.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
